Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study

This publication has 13 references indexed in Scilit:

• Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers
  Antimicrobial Agents and Chemotherapy, 2016
• Structures of Ebola virus GP and sGP in complex with therapeutic antibodies
  Nature Microbiology, 2016
• Risk factors for transmission of Ebola or Marburg virus disease: a systematic review and meta-analysis
  International Journal of Epidemiology, 2015
• Ebola viral load at diagnosis associates with patient outcome and outbreak evolution
  Journal of Clinical Investigation, 2015
• The Multiple Roles of sGP in Ebola Pathogenesis
  Viral Immunology, 2015
• Ebola virus (EBOV) infection: Therapeutic strategies
  Biochemical Pharmacology, 2015
• Clinical Presentation of Patients with Ebola Virus Disease in Conakry, Guinea
  New England Journal of Medicine, 2015
• Clinical Illness and Outcomes in Patients with Ebola in Sierra Leone
  New England Journal of Medicine, 2014
• Structures of protective antibodies reveal sites of vulnerability on Ebola virus
  Proceedings of the National Academy of Sciences, 2014
• Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice
  Proceedings of the National Academy of Sciences, 2014